Latest News and Press Releases

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash., Jan. 08, 2025 (GLOBE...

Austin, TX, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hemophilia B Gene Therapy Market Size, Trends and Insights By Treatment Type...

Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...

NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...

SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Ebvia, a biotechnology developing simple-to-use therapeutics for the treatment and prevention of COVID-19, today announces the publication entitled...

Selbyville, Delaware, March 01, 2022 (GLOBE NEWSWIRE) -- Hemophilia treatment market revenue is projected to reach USD 16 billion by 2028, according to a new research report by Global Market...

With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...

TUCSON, Ariz., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Americans, even one who is as carefully shielded as the President of the United States, continue to be infected with COVID-19. The Association of...

SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...

SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...